Related Experiment Video
Updated: Jun 26, 2025

Isolation of Double Negative αβ T Cells from the Kidney
Published on: May 16, 2014
Unveiling the hidden role of the interaction between CD36 and FcγRIIb: implications for autoimmune disorders
Chenfei He1,2, Guoying Hua3, Yong Liu4
1Center for Research in Animal Genomics, Agricultural Genome Institute at Shenzhen, Chinese Academy of Agricultural Sciences, Shenzhen, China. hechenfei@caas.cn.
Insights
This study reveals scavenger receptor CD36 (cluster of differentiation 36) is crucial in B cells for regulating autoimmune responses. Its interaction with FcγRIIb (Fc gamma receptor IIb) offers a potential therapeutic target for autoimmune diseases.
Area of Science:
- Immunology
- Cell Biology
- Autoimmunity
Background:
- The scavenger receptor CD36 (cluster of differentiation 36) is well-studied in macrophages, dendritic cells, and T cells.
- Its specific role in B cell function and metabolism remains largely unexplored.
Purpose of the Study:
- To investigate the function of CD36 in B cells.
- To identify CD36-interacting proteins within primary B cells.
- To explore the therapeutic potential of CD36-FcγRIIb interactions in autoimmunity.
Main Methods:
- Utilized Cd36fl/flMB1cre mice lacking CD36 specifically in B cells to model autoimmune responses.
- Employed mass spectrometry for identifying CD36-interacting proteins in B cells.
- Confirmed protein interactions using immunofluorescence and co-immunoprecipitation.
Main Results:
- Mice deficient in B cell CD36 showed reduced germinal center B cells and autoantibodies.
- Mass spectrometry identified 30 potential CD36-interacting partners.
- Discovered and confirmed a novel interaction between CD36 and the inhibitory Fc receptor FcγRIIb (Fc gamma receptor IIb).
- FcγRIIb deletion decreased CD36 expression in multiple B cell populations.
Conclusions:
- CD36 in B cells is a critical regulator of autoimmune disease development.
- The CD36-FcγRIIb interaction represents a promising therapeutic target for autoimmune disorders.
Background:
The role of the scavenger receptor CD36 in cell metabolism and the immune response has been investigated mainly in macrophages, dendritic cells, and T cells. However, its involvement in B cells has not been comprehensively examined.
Methods:
To investigate the function of CD36 in B cells, we exposed Cd36fl/flMB1cre mice, which lack CD36 specifically in B cells, to apoptotic cells to trigger an autoimmune response. To validate the proteins that interact with CD36 in primary B cells, we conducted mass spectrometry analysis following anti-CD36 immunoprecipitation. Immunofluorescence and co-immunoprecipitation were used to confirm the protein interactions.
Results:
The data revealed that mice lacking CD36 in B cells exhibited a reduction in germinal center B cells and anti-DNA antibodies in vivo. Mass spectrometry analysis identified 30 potential candidates that potentially interact with CD36. Furthermore, the interaction between CD36 and the inhibitory Fc receptor FcγRIIb was first discovered by mass spectrometry and confirmed through immunofluorescence and co-immunoprecipitation techniques. Finally, deletion of FcγRIIb in mice led to decreased expression of CD36 in marginal zone B cells, germinal center B cells, and plasma cells.
Conclusions:
Our data indicate that CD36 in B cells is a critical regulator of autoimmunity. The interaction of CD36-FcγRIIb has the potential to serve as a therapeutic target for the treatment of autoimmune disorders.
More Related Videos
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
Related Concept Videos
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF